Indication
melanoma
78 clinical trials
89 products
22 drugs
Product
IO102-IO103Clinical trial
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
ST101Product
sotigalimabClinical trial
A Phase II Multicenter, Open-label Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody Sotigalimab (APX005M) With or Without Stereotactic Body Radiation Therapy in Adults With Unresectable or Metastatic MelanomaStatus: Terminated, Estimated PCD: 2022-07-29
Product
TemozolomideProduct
PembrolizumabProduct
BNT111Clinical trial
Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-11-01
Product
CemiplimabProduct
SCIB1Clinical trial
A Phase 2, Multicentre, Open-Label Study of SCIB1 in Patients With Advanced Unresectable Melanoma Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-07-19
Product
CMP-001Product
NivolumabProduct
L19IL2Product
L19TNFClinical trial
A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination With Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients With Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and With Presence of Injectable MetastasesStatus: Active (not recruiting), Estimated PCD: 2028-07-01
Product
L19IL2/L19TNFProduct
EVX-02AClinical trial
A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for RecurrenceStatus: Terminated, Estimated PCD: 2023-02-28
Product
EVX-02Product
EVX-02BClinical trial
A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic MelanomaStatus: Completed, Estimated PCD: 2024-02-05
Product
KB707Product
[203Pb]VMT01Product
[212Pb]VMT01Clinical trial
A Phase I/IIa, First-In-Human, Multi-Center Dose Escalation and Dose Expansion Study of [203/212Pb]VMT01 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Patients With Previously Treated Unresectable or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open-label, Phase I Study of NEO-PTC-01 in Patients With Advanced or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-10-31
Product
NEO-PTC-01Product
IL-2Product
αPD-1 therapyProduct
SCIB1 DNA vaccineClinical trial
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)Status: Completed, Estimated PCD: 2021-04-15
Product
RetifanlimabClinical trial
A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabStatus: Recruiting, Estimated PCD: 2025-06-01
Product
SX-682Clinical trial
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-06-01
Product
IOV-4001Product
BCD-217Product
BCD-100Product
PlaceboClinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-05-31
Product
ST316Product
[68Ga]VMT02Clinical trial
A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic MelanomaStatus: Completed, Estimated PCD: 2022-09-20
Product
EncorafenibProduct
Encorafenib + BinimetinibProduct
BempegaldesleukinClinical trial
'An Open Label, Multicentre, Phase I Study to Evaluate the Impact of Moderate and Severe Hepatic Impairments on the Pharmacokinetics and Safety of Encorafenib in Combination With Binimetinib in Adult Patients With Unresectable or Metastatic BRAF V600-mutant Solid Tumors'.Status: Withdrawn, Estimated PCD: 2023-05-01
Clinical trial
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)Status: Terminated, Estimated PCD: 2022-09-22
Product
BinimetinibClinical trial
A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Pivotal Bioequivalence Study Comparing Binimetinib 3 x 15 mg and 45 mg Tablets in Healthy ParticipantsStatus: Completed, Estimated PCD: 2022-12-22
Clinical trial
An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-06-28
Product
EVX-01Clinical trial
A Randomized Phase 2 Study of Rituxan Hycela in Patients With Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade With Nivolumab and IpilimumabStatus: Active (not recruiting), Estimated PCD: 2024-09-13
Product
IpilimumabClinical trial
Phase 1 Study to Evaluate the Safety and Efficacy of TILs Transduced With IL-7 (ADP-TILIL7) in Patients With Locally Advanced or Metastatic MelanomaStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Product
ADP-TILIL7Drug
cyclophosphamideDrug
fludarabineDrug
IL-2Clinical trial
A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based TherapyStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Product
Talimogene LaherparepvecClinical trial
A Phase II Study to Evaluate the Safety and Efficacy of Rigosertib (ON 01910) Plus Pembrolizumab in Patients With Metastatic Melanoma Refractory to Immune Checkpoint BlockadeStatus: Recruiting, Estimated PCD: 2028-05-01
Product
RigosertibClinical trial
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous MelanomaStatus: Active (not recruiting), Estimated PCD: 2027-01-20
Product
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1Clinical trial
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaStatus: Recruiting, Estimated PCD: 2025-06-01
Product
SarilumabProduct
Nivolumab/RelatlimabClinical trial
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-12-13
Product
ImatinibClinical trial
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous CancersStatus: Recruiting, Estimated PCD: 2027-01-31
Product
PrednisoneDrug
sirolimusClinical trial
A Proof of Concept Study of TBio-4101 (an Autologous Selected and Expanded Tumor Infiltrating Lymphocyte [TIL] Therapy) Using Short-Term Cultured, Selected Autologous TIL Following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients With Relapsed or Refractory Melanoma (Phase 1)Status: Recruiting, Estimated PCD: 2024-08-31
Drug
TBio-4101Product
FludarabineClinical trial
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High Risk MelanomaStatus: Recruiting, Estimated PCD: 2027-02-15
Product
OpdualagClinical trial
A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable DiseaseStatus: Recruiting, Estimated PCD: 2025-01-09
Product
Poly ICLCProduct
Recombinant Flt3 LigandClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Clinical trial
MITRIC: Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clincal RespondersStatus: Recruiting, Estimated PCD: 2034-03-31
Product
Fecal Microbiota TransplantClinical trial
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced MelanomaStatus: Active (not recruiting), Estimated PCD: 2013-02-15
Product
SargramostimClinical trial
Aerosolized Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim) in Combination With Anti-PD1 Therapy for the Treatment of Metastatic Melanoma to the LungStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2027-09-30
Product
VET3-TGIProduct
Neoantigen Peptide VaccineClinical trial
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable DiseaseStatus: Active (not recruiting), Estimated PCD: 2023-04-09
Drug
T-VECClinical trial
Phase 1 Study of Trametinib + Ceritinib in Patients With Unresectable MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-10-28
Product
CeritinibProduct
TrametinibClinical trial
Phase 1 Study of the Administration of Ipilimumab Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE With Nivolumab Administered IV in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmStatus: Active (not recruiting), Estimated PCD: 2023-10-04
Product
Antiretroviral TherapyClinical trial
A Phase II Trial of Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-04-15
Product
AxitinibClinical trial
Randomized Phase II Neoadjuvant Study of PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Resectable Stage III or Oligometastatic Stage IV Melanoma (Neo-MEL-T)Status: Recruiting, Estimated PCD: 2025-01-01
Product
DostarlimabProduct
Dostarlimab and TSR-022Clinical trial
Surgery of Melanoma Metastases After Systemic Therapy - the SUMMIST TrialStatus: Withdrawn, Estimated PCD: 2023-09-03
Product
ImmunotherapyClinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
AtezolizumabDrug
AbraxaneClinical trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
DabrafenibClinical trial
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase I Study of Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-11-22
Product
Nab-paclitaxel/DanburstotugClinical trial
Intrathecal Administration of Anti-PD1/Anti-CTLA-4 in Combination With Systemic Combination of Anti-PD1/Anti-CTLA-4 in Patients With NSCLC Without Oncogenic Driver Mutation or Melanoma and Newly Diagnosed Leptomeningeal Metastasis: a Multicentric Phase I StudyStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase-2 Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma - Definition of Two Additional Stratified Patient Cohorts of Regorafenib Plus BRAF-/MEK-inhibitors in Pretreated BRAF V600-mutant Melanoma PatientsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
RegorafenibProduct
Triplet therapyClinical trial
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersStatus: Recruiting, Estimated PCD: 2027-12-30
Product
CyclophosphamideProduct
HBI 0201-ESO TCRTClinical trial
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced MelanomaStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With IpilimumabStatus: Completed, Estimated PCD: 2021-09-30
Drug
interleukin-2Clinical trial
Safe Stop IPI-NIVO Trial: Early Discontinuation of Nivolumab Upon Achieving a (Confirmed) Complete or Partial Response in Patients With Irresectable Stage III or Metastatic Melanoma Treated With First-line Ipilimumab-nivolumabStatus: Recruiting, Estimated PCD: 2025-12-01
Drug
nivolumabClinical trial
A Phase II Study of High Dose Bolus IL2 in Combination With Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 ImmunotherapyStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
IbrutinibDrug
mFOLFOX6Clinical trial
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentStatus: Active (not recruiting), Estimated PCD: 2023-09-19
Clinical trial
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion Before Tumor-Infiltrating Lymphocyte Therapy With Lifileucel in Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2025-11-27
Product
LifileucelClinical trial
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and MelanomaStatus: Recruiting, Estimated PCD: 2024-04-15
Product
Camu Camu CapsulesClinical trial
Biomarker Driven Patient Selection for Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma: A Pilot StudyStatus: Recruiting, Estimated PCD: 2027-03-01
Product
Nivolumab + RelatlimabDrug
LurbinectedinClinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Product
SonidegibClinical trial
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant CancerStatus: Active (not recruiting), Estimated PCD: 2018-05-16
Product
UprosertibClinical trial
A Phase I/II Study of PI3Kγδ Inhibitor Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Who Have Progressed on Anti-PD1 TherapyStatus: Recruiting, Estimated PCD: 2028-04-01
Product
DuvelisibClinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
UTD1Drug
AN0025Drug
doxorubicinClinical trial
A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-01
Product
GIM-531Clinical trial
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV MelanomaStatus: Active (not recruiting), Estimated PCD: 2021-10-06
Drug
fluorouracilProduct
IrinotecanClinical trial
A Phase II Study of Binimetinib in Combination With Imatinib in Patients With Advanced KIT-Mutant MelanomaStatus: Recruiting, Estimated PCD: 2024-07-31
Product
OlaparibDrug
FOLFOXIRIDrug
TiragolumabProduct
PemetrexedClinical trial
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersStatus: Active (not recruiting), Estimated PCD: 2022-10-11
Drug
SelinexorProduct
TopotecanDrug
R-CHOPDrug
VarlilumabClinical trial
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)Status: Recruiting, Estimated PCD: 2026-08-29
Clinical trial
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-11-30
Product
HydroxychloroquineClinical trial
Copy of A Phase II Trial of Pembrolizumab (Anti PD-1) Therapy Combined With Sargramostim (GM-CSF) in Unresectable or Metastatic MelanomaStatus: Withdrawn, Estimated PCD: 2024-06-10
Clinical trial
Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor ColitisStatus: Recruiting, Estimated PCD: 2030-06-30
Product
InfliximabProduct
MethylprednisoloneClinical trial
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
NavitoclaxClinical trial
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA)Status: Active (not recruiting), Estimated PCD: 2024-12-08
Drug
TocilizumabClinical trial
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable MelanomaStatus: Not yet recruiting, Estimated PCD: 2027-06-30
Product
Prebiotic Food-Enriched DietProduct
Keytruda